WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 573699
Description: ALT-946 free base is an inhibitor of advanced glycation that has been shown to improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat.
MedKoo Cat#: 573699
Name: ALT-946 free base
Chemical Formula: C5H13N5O
Exact Mass: 159.112
Molecular Weight: 159.19
Elemental Analysis: C, 37.72; H, 8.23; N, 43.99; O, 10.05
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: ALT-946 free base, ALT946 free base, ALT 946 free base
IUPAC/Chemical Name: Acetamide, N-(2-((hydrazinyliminomethyl)amino)ethyl)-
InChi Key: CKTNVANQPUCSKP-UHFFFAOYSA-N
InChi Code: 1S/C5H13N5O/c1-5(11)8-3-2-7-4-9-10-6/h4,10H,2-3,6H2,1H3,(H,7,9)(H,8,11)
SMILES Code: CC(=O)NCCN/C=N/NN
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 159.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Nenna A, Nappi F, Avtaar Singh SS, Sutherland FW, Di Domenico F, Chello M, Spadaccio C. Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease. Res Cardiovasc Med. 2015 May 23;4(2):e26949. doi: 10.5812/cardiovascmed.4(2)2015.26949. eCollection 2015 May. Review. PubMed PMID: 26393232; PubMed Central PMCID: PMC4571620.
2: Thomas MC, Baynes JW, Thorpe SR, Cooper ME. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets. 2005 Jun;6(4):453-74. Review. PubMed PMID: 16026265.
3: Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, Cooper ME. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes. 2002 Nov;51(11):3283-9. PubMed PMID: 12401720.
4: Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G, Cooper ME. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia. 2001 Jan;44(1):108-14. PubMed PMID: 11206401.